|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, October 07, 2008 ) ZURICH, Switzerland - Munogenics, Inc. signed a Global Marketing Agreement for FranTech Switzerland Licensing, (FranTech) of Zurich, Switzerland which will grant licenses into 220 countries.
Munogenics, Inc. is a bio tech pharmaceutical firm specializing in the manufacturing and marketing of immunomodulators, vaccines, and blood derivatives.
Munogenics is affiliated with the National Center of Infectious and Parasitic Diseases in Sofia, Bulgaria.
The main product of Munogenics is Respivax, which is a polybacterial immunomodulator that will be used to treat respiratory infections and compromised immune systems.
Munogenics has been in existence since 1995 and is involved with global development of four biological compounds.
"What else can serendipity be than the Universe presenting something at the time it needs to be presented in the hopes that someone will be paying close enough attention to grasp the presentation?"
The United States FDA grants IND Exception status to the discoverers of GIFT and approves a go-ahead of formal human trials!
FranTech Switzerland Ltd.
is honored by Munogenics LLC of America, by being asked to be involved in Munogenics quest to change the way the world treats cancer!
In October 2008, Munogenics LLC of the United States of America, signs a Global Marketing Agreement with Global FranTech Group. to participate in licensing their project in 220 countries to change the world!
FranTech Switzerland Ltd. has now been named "Licensing Company Representatives" for the licensing of GIFT that Munogenics and their research partners are bringing to humankind!
Philip Nadeau, CEO of Global FranTech Group, said, "We see a tremendous market Wolrdwide for Munogenics, ("GIFT") and ("CKA") licensing into 220 countries.
("GIFT") stands for Granulocyte InFusion Therapy and is the world's first, truly effective treatment for cancer! It also stands for the most vital aspect of the discovery - the GIFT ASSAY TEST.
Beginning with a serendipitous discovery in 1999 by researchers at a well-known American university school of medicine, the development of this GIFT will soon be available to humankind.
"What is GIFT ? "
("GIFT") is a treatment for cancer that for the first time in human history has already shown total cure of specific cancers (sarcoma, prostate cancer, skin cancer) in mice and that is set to begin human studies this year.
We know it sounds remarkable, and it truly is! Over the last 8 years researchers have been building on the serendipitous discovery that led to not only the development of GIFT but also of the GIFT ASSAY TEST, that can identify if one is resistant to cancers (CR or Cancer
Resistant) - or not. These two amazing discoveries WILL change the world of medicine in relation to the treatment of cancers!
The "KEY" to the door leading to the future of cancer treatment is the GIFT ASSAY TEST. It is this patented and proprietary discovery that can identify if a human or animal is, or is not, resistant to cancers...and to which cancers the subject is resistant! Without this "KEY" treatment using the GIFT is not possible.
With the benefit of the GIFT ASSAY TEST, a new chapter in assessing Risk and thus allowing a new kind of informed Risk Management has arrived.
A completely revolutionary method, using a CR subject's "OWN" natural resistance to cancer to be cryogenically saved and returned to the CR subject when they are at an age when their natural resistance to cancer wanes, only adds to this amazing GIFT!
Think of the amazing possibilities! A truly natural, non-toxic method of treatment that has already proven itself over the last 8 years to actually effectively deal with cancer!
The possibilities in the human medicine, pet/veterinary, and animal husbandry industries almost staggers the mind!
Currently funding is being sought for full development and the beginning of Phase II and Phase III trials to be held in the United States and other countries and to establish laboratories that will provide the
GIFT ASSAY TEST:
To partner treatment facilities to test their patients and make use of the results in their treatment regimen to individuals so they can assess their own status and develop a heretofore impossible Risk Management program - in concert with the advice of their doctor or cancer immunologist - to make the necessary lifestyle changes that will keep them cancer-free in their own future to set up cryogenic operations that will preserve the cancer resistant elements of a CR donor for their own personal future use to veterinarians so that companion animals - an increasing number of which are being struck with various cancers - can benefit from this GIFT to the agriculture/animal husbandry industry to deal with cancers in food animals - a serious problem - to make our animal food sources free from cancers
About FranTech Switzerland
FranTech's mission is to foster the development of Global Health Care through it's FranMedics Division with medical developers, marketers, manufactures and health care innovators of newly emerging and preemptive technologies. They offer world-class solutions for licensing and technology transfer of worldwide innovations to 220 countries for 35 years.
Munogenics is pleased to commence a strong working relationship with FranTech.
Further information can be obtained by serious, interested parties by contacting us. Scientific information can be obtained only after signing of a FranTech Switzerland Confidentiality and Non-Disclosure Agreement, although information is available on the internet and through publications such as PNAS (Proceedings of the National Academy of Sciences - www.pnas.org/).
You will notice we only provide Worlwide FranTech links from this page:
our Home pages and our FranTech Contact page.
If you would like to visit our other pages please find links to those pages from our Home pages:
www.FranTechWTC-3G.com
www.eFranTechIndonesia.com
Copyright © 2007 FranTech Switzerland.
Contact:
FranTech Switzerland
Lathell Sancho, President
Tel: + 702-677-7075
Visit us at:
www.FranTechUSA.com
www.FranTechAsia.com
www.FranTechStrategies.com
FranTech
Lathell Sancho
702-677-7075
- 
Source: EmailWire.com
|
|
|
|
